RxDoctor Payments Data

Savannah Coe, APRN

Family · Athens, TNNPI 1689348203

Payments from drug & device makers

$963in general payments, 2019–2025

Across 55 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$619
  • Novo Nordisk$190
  • Lundbeck LLC$33
  • Otsuka America Pharmaceutical, Inc.$26
  • Revance Therapeutics, Inc.$22
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$19
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$25,071
Medicare patients
95
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$76,657
MounjaroTirzepatide54$66,309
FarxigaDapagliflozin Propanediol21$29,330
EliquisApixaban21$25,826
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$15,793
TradjentaLinagliptin21$11,614
MyrbetriqMirabegron13$11,001
LinzessLinaclotide15$7,666
CorlanorIvabradine Hcl12$7,156
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm12$1,986
Omeprazole122$1,849
Celecoxib44$1,684
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,526
Albuterol Sulfate HfaAlbuterol Sulfate74$1,333
Atorvastatin Calcium103$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$190$76,65756 claims
Lilly USA, LLCMounjaro, Humulin 70-30$13$68,29566 claims
PfizerEliquis$14$25,82621 claims
AbbVieLinzess$619$7,66615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Athens

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →